1
|
Gu G, Yang JZ and Sun LX: Correlation of
graft immune composition with outcomes after allogeneic stem cell
transplantation: Moving towards a perfect transplant. Cell Immunol.
323:1–8. 2018.PubMed/NCBI View Article : Google Scholar
|
2
|
Urbano-Ispizua A, Rozman C, Pimentel P,
Solano C, de la Rubia J, Brunet S, Pérez-Oteiza J, Ferrá C, Zuazu
J, Caballero D, et al: The number of donor CD3(+) cells is the most
important factor for graft failure after allogeneic transplantation
of CD34(+) selected cells from peripheral blood from HLA-identical
siblings. Blood. 97:383–387. 2001.PubMed/NCBI View Article : Google Scholar
|
3
|
Kałwak K, Porwolik J, Mielcarek M,
Gorczyńska E, Owoc-Lempach J, Ussowicz M, Dyla A, Musiał J,
Paździor D, Turkiewicz D and Chybicka A: Higher CD34(+) and CD3(+)
cell doses in the graft promote long-term survival, and have no
impact on the incidence of severe acute or chronic
graft-versus-host disease after in vivo T cell-depleted unrelated
donor hematopoietic stem cell transplantation in children. Biol
Blood Marrow Transplant. 16:1388–1401. 2010.PubMed/NCBI View Article : Google Scholar
|
4
|
Sakiyama M, Kami M, Hori A, Imataki O,
Hamaki T, Murashige N, Kobayashi K, Kishi Y, Kojima R, Kim SW, et
al: Regimen-related toxicity following reduced-intensity stem-cell
transplantation (RIST): Comparison between seattle criteria and
national cancer center common toxicity criteria (NCI-CTC) version
2.0. Bone Marrow Transplant. 34:787–794. 2004.PubMed/NCBI View Article : Google Scholar
|
5
|
Blazar BR, Murphy WJ and Abedi M: Advances
in graft-versus-host disease biology and therapy. Nat Rev Immunol.
12:443–458. 2012.PubMed/NCBI View
Article : Google Scholar
|
6
|
Kosugi-Kanaya M, Ueha S, Abe J, Shichino
S, Shand FHW, Morikawa T, Kurachi M, Shono Y, Sudo N, Yamashita A,
et al: Long-lasting graft-derived donor T cells contribute to the
pathogenesis of chronic graft-versus-host disease in mice. Front
Immunol. 8(1842)2017.PubMed/NCBI View Article : Google Scholar
|
7
|
Danby RD, Zhang W, Medd P, Littlewood TJ,
Peniket A, Rocha V and Roberts DJ: High proportions of regulatory T
cells in PBSC grafts predict improved survival after allogeneic
haematopoietic SCT. Bone Marrow Transplant. 51:110–118.
2016.PubMed/NCBI View Article : Google Scholar
|
8
|
Li Pira G, Malaspina D, Girolami E,
Biagini S, Cicchetti E, Conflitti G, Broglia M, Ceccarelli S,
Lazzaro S, Pagliara D, et al: Selective depletion of αβ T cells and
b cells for human leukocyte antigen-haploidentical hematopoietic
stem cell transplantation. A three-year follow-up of procedure
efficiency. Biol Blood Marrow Transplant. 22:2056–2064.
2016.PubMed/NCBI View Article : Google Scholar
|
9
|
Oevermann L, Lang P, Feuchtinger T, Schumm
M, Teltschik HM, Schlegel P and Handgretinger R: Immune
reconstitution and strategies for rebuilding the immune system
after haploidentical stem cell transplantation. Ann N Y Acad Sci.
1266:161–170. 2012.PubMed/NCBI View Article : Google Scholar
|
10
|
Oevermann L and Handgretinger R: New
strategies for haploidentical transplantation. Pediatric Res.
7:418–426. 2012.PubMed/NCBI View Article : Google Scholar
|
11
|
Handgretinger R: New approaches to graft
engineering for haploidentical bone marrow transplantation. Semin
Oncol. 39:664–673. 2012.PubMed/NCBI View Article : Google Scholar
|
12
|
Vadakekolathu J and Rutella S: T-cell
manipulation strategies to prevent graft-versus-host disease in
haploidentical stem cell transplantation. Biomedicines. 5:
pii(E33)2012.
|
13
|
Prentice HG, Blacklock HA, Janossy G,
Gilmore MJ, Price-Jones L, Tidman N, Trejdosiewicz LK, Skeggs DB,
Panjwani D, Ball S, et al: Depletion of T lymphocytes in donor
marrow prevents significant graft-versus-host disease in matched
allogeneic leukaemic marrow transplant recipients. Lancet.
1:472–476. 1984.PubMed/NCBI View Article : Google Scholar
|
14
|
Saad A and Lamb LS: Ex vivo T-cell
depletion in allogeneic hematopoietic stem cell transplant: past,
present and future. Bone Marrow Transplant. 52:1241–1248.
2017.PubMed/NCBI View Article : Google Scholar
|
15
|
Urbano-Ispizua A, Rozman C, Pimentel P,
Solano C, de la Rubia J, Brunet S, Pérez-Oteyza J, Ferrá C, Zuazu
J, Caballero D, et al: Risk factors for acute graft-versus-host
disease in patients undergoing transplantation with CD34+ selected
blood cells from HLA-identical siblings. Blood. 100:724–727.
2002.PubMed/NCBI View Article : Google Scholar
|
16
|
Gaziev J, Isgrò A, Marziali M, Daniele N,
Gallucci C, Sodani P, Simone MD, Adorno G, Paciaroni K, Andreani M,
et al: Higher CD3(+) and CD34(+) cell doses in the graft increase
the incidence of acute GVHD in children receiving BMT for
thalassemia. Bone Marrow Transplant. 47:107–114. 2012.PubMed/NCBI View Article : Google Scholar
|
17
|
Czerw T, Labopin M, Schmid C, Cornelissen
JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure
B, et al: High CD3+ and CD34+ peripheral blood stem cell grafts
content is associated with increased risk of graft-versus-host
disease without beneficial effect on disease control after
reduced-intensity conditioning allogeneic transplantation from
matched unrelated donors for acute myeloid leukemia-an analysis
from the acute leukemia working party of the European society for
blood and marrow transplantation. Oncotarget. 7:27255–27266.
2016.PubMed/NCBI View Article : Google Scholar
|
18
|
Anderson BE, Taylor PA, McNiff JM, Jain D,
Demetris AJ, Panoskaltsis-Mortari A, Ager A, Blazar BR, Shlomchik
WD and Shlomchik MJ: Effects of donor T-cell trafficking and
priming site on graft-versus-host disease induction by naive and
memory phenotype CD4 T cells. Blood. 111:5242–5251. 2008.PubMed/NCBI View Article : Google Scholar
|
19
|
Pastore D, Delia M, Mestice A, Carluccio
P, Perrone T, Gaudio F, Curci P, Rossi AR, Ricco A and Specchia G:
CD3+/Tregs ratio in donor grafts is linked to acute
graft-versus-host disease and immunologic recovery after allogeneic
peripheral blood stem cell transplantation. Biol Blood Marrow
Transplant. 18:887–893. 2012.PubMed/NCBI View Article : Google Scholar
|
20
|
Pabst C, Schirutschke H, Ehninger G,
Bornhäuser M and Platzbecker U: The graft content of donor T cells
expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of
acute graft versus host disease after transplantation of allogeneic
peripheral blood stem cells from unrelated donors. Clin Cancer Res.
13:2916–2922. 2007.PubMed/NCBI View Article : Google Scholar
|
21
|
Rezvani K, Mielke S, Ahmadzadeh M, Kilical
Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander
R and Barrett AJ: High donor FOXP3-positive regulatory T-cell
(Treg) content is associated with a low risk of GVHD following
HLA-matched allogeneic SCT. Blood. 108:1291–1297. 2006.PubMed/NCBI View Article : Google Scholar
|
22
|
Mohty M, Bagattini S, Chabannon C, Faucher
C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, et al:
CD8+ T cell dose affects development of acute graft-vs-host disease
following reduced-intensity conditioning allogeneic peripheral
blood stem cell transplantation. Exp Hematol. 32:1097–1102.
2004.PubMed/NCBI View Article : Google Scholar
|
23
|
Chang YJ, Zhao XY, Huo MR and Huang XJ:
Expression of CD62L on donor CD4(+) T cells in allografts:
Correlation with graft-versus-host disease after unmanipulated
allogeneic blood and marrow transplantation. J Clin Immunol.
29:696–704. 2009.PubMed/NCBI View Article : Google Scholar
|